Mechanisms of stearoyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer

硬脂酰辅酶 A 去饱和酶抑制剂敏感性和癌症获得性耐药性的机制

阅读:6
作者:Nicole Oatman, Nupur Dasgupta, Priyanka Arora, Kwangmin Choi, Mruniya V Gawali, Nishtha Gupta, Sreeja Parameswaran, Joseph Salomone, Julie A Reisz, Sean Lawler, Frank Furnari, Cameron Brennan, Jianqiang Wu, Larry Sallans, Gary Gudelsky, Pankaj Desai, Brian Gebelein, Matthew T Weirauch, Angelo D'Ales

Abstract

The lipogenic enzyme stearoyl CoA desaturase (SCD) plays a key role in tumor lipid metabolism and membrane architecture. SCD is often up-regulated and a therapeutic target in cancer. Here, we report the unexpected finding that median expression of SCD is low in glioblastoma relative to normal brain due to hypermethylation and unintentional monoallelic co-deletion with phosphatase and tensin homolog (PTEN) in a subset of patients. Cell lines from this subset expressed undetectable SCD, yet retained residual SCD enzymatic activity. Unexpectedly, these lines evolved to survive independent of SCD through unknown mechanisms. Cell lines that escaped such genetic and epigenetic alterations expressed higher levels of SCD and were highly dependent on SCD for survival. Last, we identify that SCD-dependent lines acquire resistance through a previously unknown FBJ murine osteosarcoma viral oncogene homolog B (FOSB)-mediated mechanism. Accordingly, FOSB inhibition blunted acquired resistance and extended survival of tumor-bearing mice treated with SCD inhibitor.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。